Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Study Overview
=================
Brief Summary
-----------------
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

Detailed Description
-----------------
Approximately 160 patients will be randomly assigned in a 1:1 ratio to receive milademetan or trabectedin. Randomization will be stratified by the ECOG performance status (0 or 1) and number of prior treatments (≤ 2 or > 2) for the patient's liposarcoma. Patients will receive study drug (i.e., milademetan or trabectedin) until reaching unequivocal disease progression (RECIST v.1.1) as determined by the Investigator, experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. Patients may be treated beyond tumor progression if they are experiencing clinical benefit based on the assessment of the Investigator in discussion with the Medical Monitor. All patients will be followed for documentation of disease progression and survival information (i.e., date and cause of death) and subsequent treatment information (i.e., date/duration of treatment, response, and subsequent disease progression). Long-term follow-up will continue every 12 weeks (± 7 days) until the endpoint of death, the patient is lost to follow-up, or for 24 months following the final dose of study drug, whichever comes first.

Official Title
-----------------
A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma

Conditions
-----------------
Dedifferentiated Liposarcoma

Intervention / Treatment
-----------------
* Drug: RAIN-32
* Drug: Trabectedin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed DD liposarcoma, with or without a WD component (WD/DD liposarcoma). Note: Patient must be willing to provide an archival tumor tissue sample that is ≤ 3 years old and of adequate quality or willing to provide a fresh pretreatment biopsy sample Advanced unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) and/or metastatic WD/DD liposarcoma Measurable tumor lesion(s) in accordance with RECIST version 1.1 Received 1 or more systemic cancer therapy regimens, including at least 1 anthracycline-based regimen, and had radiographic progressive disease (per RECIST version 1.1) within 6 months before the Screening Visit Resolution of any clinically relevant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy ECOG performance status of 0 or 1 Adequate bone marrow function: Platelet count ≥ 100 × 10^9/L Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ≥ 1.5 × 10^9/L Adequate hepatic function: Alanine aminotransferase and aspartate aminotransferase ≤ 3 × upper limit of normal (ULN) if no liver metastases are present; ≤ 5 × ULN if liver metastases are present Total bilirubin ≤ 1.5 × ULN, or ≤ 3 x ULN in the setting of Gilbert's disease Exclusion Criteria: Prior treatment with any mouse double minute 2 (MDM2) inhibitor or trabectedin Other primary malignancies that have required systemic antineoplastic treatment within the previous 2 years, except for localized cancers that have apparently been cured Gastrointestinal conditions that could affect the absorption of milademetan, in the opinion of the Investigator Uncontrolled infection within the last 7 days requiring IV antibiotics, antivirals, or antifungals Known HIV infection or active Hepatitis B or C Untreated brain metastases. Note: Patients who require steroids for brain metastases must be on a stable or tapering dose of corticosteroids for at least 2 weeks before randomization. If applicable, patients must complete stereotactic radiosurgery 7 days before and whole brain radiotherapy 21 days before their first dose of study drug. Investigational therapy administered within the 28 days or 5 half lives: Cytochrome P450 3A4 isozyme strong inhibitor: 5 elimination half-lives CYP3A strong or moderate inducers: 4 weeks Systemic anticancer therapy or investigational therapy 3 weeks or 5 half-lives, Immunotherapy with checkpoint inhibitor: 4 weeks Curative-intent radiation therapy ≤ 4 weeks or palliative radiation therapy, Uncontrolled or significant cardiovascular disease: QTcF at rest, where the mean QTcF interval is > 480 milliseconds Myocardial infarction within 6 months Uncontrolled angina pectoris within 6 months New York Heart Association Class 3 or 4 congestive heart failure Uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RAIN-32 (Milademetan)<br>260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle. | Drug: RAIN-32<br>* 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle<br>* Other names: Milademetan;|
| Active Comparator: Trabectedin<br>1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks. | Drug: Trabectedin<br>* 1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks<br>* Other names: Yondelis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare progression-free survival (PFS) as determined by Blinded Independent Central Review (BICR) between the milademetan treatment arm and trabectedin control arm |  | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) | OS as measured from the date of randomization to date of death by any cause | 4 years | 
| Disease control rate (DCR) | DCR defined as the percentage of patients who have achieved CR, PR, or SD for ≥ 8 weeks | 4 years | 
| Objective response rate (ORR) | ORR defined as the percentage of patients who achieve a confirmed CR or PR | 4 years | 
| Duration of response (DOR) | DOR defined as the time from date of first response to date of disease progression or death | 4 years | 
| PFS by Investigator assessments | PFS defined as the time from randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, based on Investigator assessments | 4 years | 
| Number of participants with treatment-emergent adverse events until approximately 30 days after the last study drug |  | 4 years | 
| Evaluate the patient-reported outcomes by using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire, Core 30 (QLQ-C30) |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sarcoma, MDM2, pleomorphic liposarcoma